In vitro toxicology of tobacco products. The contractor shall conduct an assessment of tobacco products and tobacco product constituents? Genetic toxicology in in vitro assays: comparative in vitro…
Ended Awarded Last action
- Contract number
- HHSF22301001T
- Awardee
-
Lovelace Biomedical And Environmental Research Institute, Inc. UEI N1UBCLRAPNG6
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $679,680
Award facts
- Opportunity
-
- 900000000 Solicitation number
- Contract value 100% obligated
- $679,680.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- PSC
- AJ11 General Science And Technology R&D Services; General Science And Technology; Basic Research
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Albuquerque, NM 87108, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $679,680 |
About this award
This is a firm-fixed-price delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI) for $679,680.00. The contract is part of a larger In Vivo Toxicology of Tobacco 2015-2020 Indefinite Delivery, Indefinite Quantity (IDIQ) contract. Under this task order, LBERI will conduct an assessment of tobacco products and tobacco product constituents' genetic toxicology using in vitro assays to compare the mutagenicity, cytotoxicity, and genotoxicity of conventional cigarettes versus electronic cigarettes. The contract has no set-aside designation and is scheduled for completion by June 30, 2017.
Description
In vitro toxicology of tobacco products. The contractor shall conduct an assessment of tobacco products and tobacco product constituents? Genetic toxicology in in vitro assays: comparative in vitro toxicity of conventional cigarettes versus electronic cigarettes - mutagenicity, cytotoxicity, and genotoxicity.
Quick answers
Who was awarded contract HHSF22301001T?
HHSF22301001T was awarded to Lovelace Biomedical And Environmental Research Institute, Inc. by Food and Drug Administration (Department of Health and Human Services) on August 27, 2015.
How much is contract HHSF22301001T worth?
The government has obligated $679,680 on HHSF22301001T.
Is contract HHSF22301001T an order under another contract?
Yes. HHSF22301001T is a delivery order under HHSF223201510001I, an indefinite delivery contract, on In Vivo Toxicology of Tobacco 2015-2020.
Was contract HHSF22301001T competed?
The extent of competition for HHSF22301001T was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award